இணைந்து வருவாய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress

Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesDineshv patelJanssen biotech incPrnewswire protagonist therapeutics incEuropean hematology associationProtagonist therapeutics incExchange commissionDevelopment rd expensesDrug administration breakthrough therapy designationVirtual congressChief executiveDrug administrationBreakthrough therapySubcutaneous injectable hepcidin mimeticPolycythemia veraBreakthrough therapy designation

Nirsevimab MEDLEY Phase II/III trial demonstrated favourable safety and tolerability profile in infants

Nirsevimab MEDLEY Phase II/III trial demonstrated favourable safety and tolerability profile in infants
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomSanofi pasteurJoseph domachowskeAstrazeneca synagisDrug administrationEuropean medicines agency priorityCompany on twitter astrazenecaGlobal head of researchUniversity of new yorkNational medical products administrationChina centerState universityUpstate medical centerExecutive vice president

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Nirsevimab PhII/III trial confirms safety profile

and tolerability profile in infants at high risk of RSV The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV season. 1 The trial assessed the safety of nirsevimab in infants with chronic lung disease (CLD), congenital heart disease (CHD) and/or prematurity. Occurrence of treatment emergent adverse events (TEAEs) or treatment emergent serious adverse events (TESAEs) were similar between groups. 1 Nirsevimab is a long-acting antibody, using AstraZeneca s proprietary YTE technology, being developed by AstraZeneca and Sanofi with the potential

New yorkUnited statesUnited kingdomSanofi pasteurJoseph domachowskeAstrazeneca synagisAdrian kempHospitalizations among children aged lancet glob healthCenters for diseaseDrug administrationEuropean medicines agency priorityCompany on twitter astrazenecaGlobal head of researchUniversity of new yorkInvestor relations teamNational medical products administration

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Nirsevimab Phase III trial met primary endpoint

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Nirsevimab Phase III trial met primary endpoint
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSanofi pasteurWilliam mullerJean franois toussaintAnn roberth lurieAdrian kempEuropean medicines agency priorityNorthwestern university feinberg school of medicineCompany on twitter astrazenecaGlobal head of researchBurden of communityOxford vaccines groupAmerican academy of pediatrics immunoprophylaxisChina centerCenters for disease

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Regulatory guidance anticipated in the first half of 2021 for registrational clinical development plan of investigational drug, rusfertide (PTG-300), for polycythemia vera Company expects to share findings from ongoing hereditary hemochromatosis study for rusfertide (PTG-300) in the second half of 2021 Strong cash position to fund planned operations through the first half of 2024 Management to host conference call today at 4:30 p.m. EST News provided by Share this article Share this article NEWARK, Calif., March 10, 2021 /PRNewswire/ Protagonist Therapeutics, Inc. ( Protagonist or the Company ) (Nasdaq: PTGX) today reported financial results and provided a corporate update for the fourth quarter and full year ended December 31, 2020.

United statesDineshv patelCompany nasdaqPrnewswire protagonist therapeutics incDrug administrationProtagonist therapeutics incAmerican society of hematologyExchange commissionDevelopment rd expensesEuropean medicines agencyProtagonist presidentChief executiveFast trackRed blood cellsAmerican societyCash equivalents